Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Serotonin Syndrome 3Neuroendocrine Tumors 3Pancreatic Neoplasms 1Diarrhea 1Carcinoid Tumor 1Biliary Tract Neoplasms 1

Interventions

lanreotide 3cabozantinib 3Nivolumab 3Everolimus 3pasireotide 2lutetium Lu 177 dotatate 2ganitumab 2Sunitinib 2Octreotide 2Erlotinib Hydrochloride 2Bevacizumab 2zimberelimab 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1aflibercept 1Temozolomide 1Somatostatin 1Random Allocation 1Ramucirumab 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × telotristat ethyl × Clear all
NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡